Kyverna Therapeutics Inc. (KYTX) Stock: Evaluating the Annual Growth

The volatility ratio for the week is 8.80%, and the volatility levels for the last 30 days are 6.93% for Kyverna Therapeutics Inc. The simple moving average for the past 20 days is -15.88% for KYTX’s stock, with a -18.88% simple moving average for the past 200 days.

Is It Worth Investing in Kyverna Therapeutics Inc. (NASDAQ: KYTX) Right Now?

Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

The public float for KYTX is 17.78M, and currently, short sellers hold a 5.65% ratio of that float. The average trading volume of KYTX on April 04, 2024 was 540.37K shares.

KYTX) stock’s latest price update

Kyverna Therapeutics Inc. (NASDAQ: KYTX)’s stock price has increased by 1.67 compared to its previous closing price of 21.92. However, the company has seen a -7.57% decrease in its stock price over the last five trading sessions. Seeking Alpha reported 2024-02-10 that U.S. IPO Weekly Recap: Autoimmune Biotech Kyverna Therapeutics Gains 37% In A Six IPO Week

Analysts’ Opinion of KYTX

Many brokerage firms have already submitted their reports for KYTX stocks, with Wells Fargo repeating the rating for KYTX by listing it as a “Overweight.” The predicted price for KYTX in the upcoming period, according to Wells Fargo is $44 based on the research report published on March 04, 2024 of the current year 2024.

Morgan Stanley, on the other hand, stated in their research note that they expect to see KYTX reach a price target of $40. The rating they have provided for KYTX stocks is “Overweight” according to the report published on March 04th, 2024.

Leerink Partners gave a rating of “Outperform” to KYTX, setting the target price at $48 in the report published on March 04th of the current year.

KYTX Trading at -18.88% from the 50-Day Moving Average

After a stumble in the market that brought KYTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -36.44% of loss for the given period.

Volatility was left at 6.93%, however, over the last 30 days, the volatility rate increased by 8.80%, as shares sank -20.77% for the moving average over the last 20 days.

During the last 5 trading sessions, KYTX fell by -7.13%, in comparison to the 20-day moving average, which settled at $26.20. In addition, Kyverna Therapeutics Inc. saw -25.72% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at KYTX starting from GILEAD SCIENCES, INC., who purchase 910,000 shares at the price of $22.00 back on Feb 12 ’24. After this action, GILEAD SCIENCES, INC. now owns 4,126,119 shares of Kyverna Therapeutics Inc., valued at $20,020,000 using the latest closing price.

Northpond Ventures III GP, LLC, the Former 10% Owner of Kyverna Therapeutics Inc., purchase 450,000 shares at $22.00 during a trade that took place back on Feb 12 ’24, which means that Northpond Ventures III GP, LLC is holding 450,000 shares at $9,900,000 based on the most recent closing price.

Stock Fundamentals for KYTX

The liquidity ratio also appears to be rather interesting for investors as it stands at 3.05.

Conclusion

To put it simply, Kyverna Therapeutics Inc. (KYTX) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts